Supplementary Material

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Todd M. Bauer[1,2], Kathleen N. Moore[1,3], Janet S. Rader[4], Fiona Simpkins[5], Alain C. Mita[6], J. Thaddeus Beck[7], Lowell Hart[8], Quincy Chu[9], Amit Oza[10], Anna V. Tinker[11], Esteban Rodrigo Imedio[12]*, Sanjeev Kumar[12], Ganesh Mugundu[13]*, Suzanne Jenkins[12], Juliann Chmielecki[14]*, Suzanne Jones[1], David Spigel[1,2], Siqing Fu[15]

[1]Sarah Cannon Research Institute, Nashville, TN, USA; [2]Tennessee Oncology, PLLC, Nashville, TN, USA; [3]Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA; [4]Medical College of Wisconsin, Milwaukee, WI, USA; [5]Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; [6]Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, CA, USA; [7]Highlands Oncology Group, Springdale, AR, USA; [8]Sarah Cannon Research Institute, Fort Myers, FL, USA; [9]University of Alberta Cross Cancer Institute, Edmonton, Canada; [10]Princess Margaret Cancer Centre, Toronto, Canada; [11]BC Cancer, Vancouver, Canada; [12]Precision Medicine and Biosamples, R&D, AstraZeneca, Cambridge, UK; [13]Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, Boston, MA, USA; [14]Translational Medicine, Oncology Research and Early Development, AstraZeneca, Boston, MA, USA; [15]The University of Texas MD Anderson Cancer Center, Houston, TX, USA

*Author is no longer an employee of AstraZeneca

Corresponding author:

Siqing Fu, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Phone: 713-792-4318; e-mail: siqingfu@mdanderson.org

Supplementary Figure S1. Patient disposition across Part A (safety lead-in) and Part B (expansion cohorts)



[a]Lost to follow-up as a result of issues with insurance; [b]One patient in the TNBC, biomarker-negative cohort (increased worsening of AEs and increase in tumoral markers) and two in the ovarian cancer BRCAm, PARPi failure cohort (clinical progression). *AE* adverse event, *BRCAm* breast cancer gene 1/2 mutation, *N* number of patients enrolled, *n* number of patients, *PARPi* poly(ADP-ribose) polymerase inhibitor, *TNBC* triple-negative breast cancer

Supplementary Figure S2. Progression-free survival (PFS) across all tumor types



Ovarian cancer, BRCAwt: 16/12*	16	9	5	1	1	1	0
Ovarian cancer, BRCAm, PARPi failure: 30/19*	30	12	3	2	1	1	0
TNBC, *CCNE1/MYC/MYCL1/MYCN* non-amplified: 13/8*	13	3	0				
TNBC, *CCNE1/MYC/MYCL1/MYCN* amplified: 6/6*	6	1	0				
SCLC, *CCNE1/MYC/MYCL1/MYCN* non-amplified: 12/11*	12	3	2	1	0		
SCLC, *CCNE1/MYC/MYCL1/MYCN* amplified: 3/3*	3	1	0				
Part B expansion cohorts: 80/59*	80	29	10	4	2	2	0

*Number of patients in the full analysis set/number of events. *BRCAm* breast cancer gene 1/2 mutation, *BRCAwt* breast cancer gene 1/2 wild type, *CCNE1* cyclin E1, *PARPi* poly(ADP-ribose) polymerase inhibitor, *SCLC* small-cell lung cancer, *TNBC* triple-negative breast cancer

Supplementary Figure S3. Waterfall plot of target lesion size and best percentage change from baseline in all cohorts (full analysis set)



RECIST version 1.1 partial response: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; progressive disease: ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. *BRCAm* breast cancer gene 1/2 mutation, *BRCAwt* breast cancer gene 1/2 wild type, *CCNE1* cyclin E1, *PARPi* poly(ADP-ribose) polymerase inhibitor, *SCLC* small-cell lung cancer, *TNBC* triple-negative breast cancer

Supplementary Figure S4. Clinical pharmacokinetics



Plasma concentrations of adavosertib at 175 mg bid (day 3 exposure, geometric mean ± standard deviation). *bid* twice a day, IC_{50} half-maximal inhibitory concentration, *pCDK1* phosphorylated cyclin-dependent kinase 1